PGLYRP1 and breast cancer: Higher circulating levels of PGLYRP1, CAMP, MMP9 and CEACAM8 prior to and after the first dose of DOX chemotherapy may further contribute to progressive cardiovascular disorders in breast cancer survivors and may potentially predict the risk of both acute subclinical and late cardiotoxicity.